NECTIN4 and neoplasm: While largely thought to represent an on‐target, off‐tumor effect due to Nectin‐4 expression on skin cells, dermatologic toxicities have been frequently observed with other MMAE payload‐containing ADCs, such as brentuximab vedotin and polatuzumab vedotin, suggesting a possible role of MMAE in their pathogenesis [29, 36, 37, 38, 39].